Drug intelligence / Profile preview

CVL009

Development stage: Unknown
Lead developer: Convalife Pharmaceutical
Modality: Small Molecules

Overview

CVL009 is an investigational small molecule drug developed by Convalife (Shanghai) for the treatment of non-small cell lung cancer (NSCLC) with EGFR exon 18 mutations. It is currently being evaluated in a Phase 2 clinical trial (NCT06029816). The precise mechanism of action and molecular target have not been publicly disclosed as of June 2025. The drug appears to be designed as a targeted therapy for patients whose tumors harbor specific EGFR mutations, which are known to drive oncogenesis in certain subsets of NSCLC.

Beyond the preview

Go deeper on CVL009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CVL009.

Explore the full profile